![Game changer for hepatitis C diagnosis – NCI Division of Cancer Prevention](https://oncodaily.com/pub/uploads/2024/07/FDA.jpg)
Game changer for hepatitis C diagnosis – NCI Division of Cancer Prevention
NCI Division of Cancer Prevention shared a post on LinkedIn:
“Cancer prevention can sometimes mean treating a chronic disease or infection that, left untreated, can lead to cancer, as can happen with a chronic hepatitis C virus (HCV) infection. Getting tested for HCV is important because an HCV infection is curable.
In June, the FDA granted U.S. marketing authorization for the first rapid hepatitis C virus test that can be used in patient care settings and deliver results in about one hour.
The new technology – validated through a collaboration between RADx Tech at The National Institutes of Health, FDA and Centers for Disease Control and Prevention – could help patients with positive tests begin treatment right away, rather than the current approach, which requires lengthy laboratory processing.
Read more about this game changer for hepatitis C diagnosis.”